SAN FRANCISCO and NEW YORK, Feb. 24, 2025 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced ...
Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential pivotal Phase 3 trial of novel combination in ...
Clinical trial collaboration and supply agreement enables pivotal Phase 3 OPERA-02 clinical trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancer; trial ...
This agreement unites Worldwide's three decades of clinical execution excellence—recognized with 11 consecutive CRO Leadership Awards—with NetraMark's advanced NetraAI platform, an explainable AI ...
Microbot Medical Inc. MBOT has received Institutional Review Board approval and entered into a Clinical Trial Agreement with Baptist Hospital of Miami. This agreement will involve the collaboration of ...
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, ...
SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, ...
This agreement unites Worldwide's three decades of clinical execution excellence—recognized with 11 consecutive CRO Leadership Awards—with NetraMark's advanced NetraAI platform, an explainable AI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback